ReviewWorld journal of gastroenterology2014
Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03715673 (Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease), which is not on this map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.Rheumatology (Oxford, England) · 2026Pooled it
- Circulating cell adhesion molecules as biomarkers in inflammatory bowel disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Epidemiology and Risk Factors of Portal Venous System Thrombosis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Thrombotic Risk and Hemostatic Profiles in Pediatric Inflammatory Bowel Disease: Association with Disease Activity.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Arterial Thrombosis in Severe Ulcerative Colitis: A Case-Based Narrative Review of Current Evidence.Biomedicines · 2026Review
- Inflammatory Bowel Disease Is Associated With Persistent Functional Impairment and Increased Short- and Long-Term Complications Following Total Knee Arthroplasty.Orthopedic reviews · 2026Article
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- Serum Levels of Coagulation Factors in Patients with Inflammatory Bowel Disease.Iranian journal of pathology · 2026Article
- Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement.Scientific reports · 2025Article
- Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases.Current issues in molecular biology · 2025Review
- Coagulation Status Assessment in Dogs with Chronic Enteropathy Using Viscoelastic Point-of-Care Coagulation Monitor.Animals : an open access journal from MDPI · 2025Article
- Fibrinogen-to-albumin ratio: a new biomarker to identify inflammatory bowel disease in active stage.Frontiers in medicine · 2025Article
- Thromboembolic and cardiovascular risk profiles in patients with ulcerative colitis initiating advanced therapies.Therapeutic advances in gastroenterology · 2025Article
- Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment.Journal of inflammation research · 2025Article
- Subtypes of Venous Thromboembolism in Inflammatory Bowel Disease: A Nationwide Assessment.Clinical research and clinical trials · 2024Article
- Uncovering novel therapeutic clues for hypercoagulable active ulcerative colitis: novel findings from old data.Gastroenterology report · 2024Article
- Influence of Inflammatory Bowel Disease on Patients Undergoing Primary Total Joint Arthroplasty: A Systematic Review and Meta-analysis of Cohort Studies.Orthopaedic journal of sports medicine · 2023Review
- Cavernous sinus thrombosis in ulcerative colitis recurrent after pregnancy: A case report.Clinical case reports · 2023Article
- Basilar artery stroke in Crohn's disease treated with endovascular thromboembolectomy.BMJ case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercoagulability observed in patients with inflammatory bowel diseases (IBD) may lead to thromboembolic events (TE), which affect the venous and arterial systems alike and are an important factor in patients' morbidity and mortality. The risk of TE in IBD patients has been demonstrated to be approximately three-fold higher as compared to the general population. The pathogenesis of thrombosis in IBD patients is multifactorial and not fully explained. The most commonly listed factors include genetic and immune abnormalities, disequilibrium between procoagulant and anticoagulant factors, although recently, the role of endothelial damage as an IBD-triggering factor is underlined. Several studies report that the levels of some coagulation enzymes, including fibrinogen, factors V, VII, VIII, active factor XI, tissue factor, prothrombin fragment 1 + 2 and the thrombin-antithrombin complex, are altered in IBD patients. It has been demonstrated that there is a significant decrease of tissue plasminogen activator level, a marked increase of plasminogen activator inhibitor type 1 and thrombin-activable fibrinolysis inhibitor, a significantly lower level of antithrombin III and tissue factor pathway inhibitor. IBD patients have been also observed to produce an increased amount of various anticoagulant antibodies. Hyperhomocysteinemia, which is a potential risk factor for TE was also observed in some IBD patients. Further studies are necessary to assess the role of coagulation abnormalities in IBD etiology and to determine indications for thromboprophylactic treatment in patients at high risk of developing TE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.